Date: 21 September 2026
Time: 09:00
Duration: 3 days
Location: Frankfurt, Germany
Cost: Register online for more information.
Organiser: Marcus Evans
This conference will explore how pharmaceutical R&D leaders can redesign decision-making, governance and operating models to improve development success, portfolio productivity and probability of success amid revenue disruption, pricing reform, and growing regulatory and competitive pressure across Europe.
Sessions will examine evidence-based kill criteria, portfolio and platform prioritisation, build-versus-buy and divestiture decisions, and the earlier integration of regulatory, reimbursement and market access considerations into investment decisions. Discussions will also address how EU HTA requirements and country-specific pricing constraints can be incorporated into R&D capital allocation. Contact riak@marcusevanscy.com for registration information.